Scarica l'app Stockscreener
149.61
0.21%
-0.31
Dopo l'orario di chiusura:
149.65
0.04
+0.03%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché GILD Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$149.92
Aprire:
$150
Volume 24 ore:
4.92M
Relative Volume:
0.67
Capitalizzazione di mercato:
$185.51B
Reddito:
$29.79B
Utile/perdita netta:
$9.22B
Rapporto P/E:
20.36
EPS:
7.3494
Flusso di cassa netto:
$10.23B
1 W Prestazione:
+1.03%
1M Prestazione:
+14.90%
6M Prestazione:
-0.28%
1 anno Prestazione:
+32.74%
Intervallo 1D:
$148.83
$152.55
Intervallo di 1 settimana:
$143.18
$152.55
Portata 52W:
$108.46
$157.29
Gilead Sciences Inc Stock (GILD) Company Profile
Nome
Gilead Sciences Inc
Settore
Industria
Telefono
(650) 574-3000
Indirizzo
333 LAKESIDE DR, FOSTER CITY, CA
Compare GILD vs LLY, JNJ, ABBV, MRK, NVS
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
149.61 | 177.86B | 29.79B | 9.22B | 10.23B | 7.3494 |
LLY
Lilly Eli Co
|
1,160.08 | 1.11T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
275.21 | 644.33B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
261.72 | 462.68B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
151.64 | 367.58B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
162.46 | 296.97B | 54.66B | 13.58B | 16.05B | 7.0171 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-10 | Iniziato | Jefferies | Buy |
| 2026-02-20 | Iniziato | Barclays | Equal Weight |
| 2026-02-11 | Reiterato | Needham | Buy |
| 2026-01-07 | Ripresa | UBS | Buy |
| 2025-11-24 | Ripresa | Truist | Buy |
| 2025-11-13 | Iniziato | Scotiabank | Sector Outperform |
| 2025-08-19 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2025-08-08 | Aggiornamento | Truist | Hold → Buy |
| 2025-07-25 | Aggiornamento | Needham | Hold → Buy |
| 2025-04-22 | Ripresa | Cantor Fitzgerald | Overweight |
| 2025-03-04 | Reiterato | Oppenheimer | Outperform |
| 2025-02-18 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2025-02-13 | Aggiornamento | DZ Bank | Hold → Buy |
| 2025-01-10 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | Ripresa | BofA Securities | Buy |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-11-14 | Iniziato | Citigroup | Buy |
| 2024-11-08 | Downgrade | Maxim Group | Buy → Hold |
| 2024-10-21 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | Iniziato | Bernstein | Outperform |
| 2024-10-07 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | Reiterato | Maxim Group | Buy |
| 2024-04-24 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2024-02-22 | Downgrade | Truist | Buy → Hold |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-09-08 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2023-09-06 | Iniziato | HSBC Securities | Reduce |
| 2023-07-24 | Reiterato | Barclays | Equal Weight |
| 2023-05-16 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | Ripresa | Piper Sandler | Overweight |
| 2023-01-03 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | Ripresa | BofA Securities | Neutral |
| 2022-12-09 | Downgrade | DZ Bank | Buy → Hold |
| 2022-10-31 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2022-10-28 | Reiterato | BMO Capital Markets | Market Perform |
| 2022-10-28 | Reiterato | Cowen | Outperform |
| 2022-10-28 | Reiterato | JP Morgan | Overweight |
| 2022-10-28 | Reiterato | Jefferies | Buy |
| 2022-10-28 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | Reiterato | RBC Capital Mkts | Outperform |
| 2022-10-28 | Aggiornamento | Truist | Hold → Buy |
| 2022-10-28 | Reiterato | Wells Fargo | Equal Weight |
| 2022-10-04 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-07-13 | Iniziato | Cantor Fitzgerald | Neutral |
| 2022-05-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2022-02-28 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | Reiterato | BMO Capital Markets | Outperform |
| 2022-02-02 | Reiterato | BofA Securities | Neutral |
| 2022-02-02 | Reiterato | RBC Capital Mkts | Outperform |
| 2022-02-02 | Reiterato | Truist | Hold |
| 2022-02-02 | Reiterato | Wells Fargo | Equal Weight |
| 2022-01-28 | Aggiornamento | Argus | Hold → Buy |
| 2022-01-06 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | Ripresa | Wells Fargo | Equal Weight |
| 2021-12-06 | Iniziato | Goldman | Neutral |
| 2021-11-19 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | Ripresa | Piper Sandler | Neutral |
| 2021-10-20 | Ripresa | Cowen | Outperform |
| 2021-07-30 | Reiterato | BMO Capital Markets | Market Perform |
| 2021-07-30 | Reiterato | RBC Capital Mkts | Outperform |
| 2021-04-01 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | Aggiornamento | Redburn | Neutral → Buy |
| 2021-01-19 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-11-03 | Ripresa | Morgan Stanley | Equal-Weight |
| 2020-10-28 | Iniziato | UBS | Neutral |
| 2020-09-30 | Ripresa | Jefferies | Buy |
| 2020-09-15 | Aggiornamento | Maxim Group | Hold → Buy |
| 2020-07-31 | Reiterato | Credit Suisse | Neutral |
| 2020-07-31 | Reiterato | Morgan Stanley | Equal-Weight |
| 2020-07-31 | Reiterato | Piper Sandler | Overweight |
| 2020-07-31 | Reiterato | RBC Capital Mkts | Outperform |
| 2020-07-31 | Reiterato | SunTrust | Hold |
| 2020-07-31 | Reiterato | Wells Fargo | Equal Weight |
| 2020-07-20 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | Aggiornamento | SunTrust | Sell → Hold |
| 2020-05-01 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-05-01 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | Downgrade | SunTrust | Hold → Sell |
| 2020-04-27 | Downgrade | UBS | Buy → Neutral |
| 2020-04-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | Downgrade | CFRA | Hold → Sell |
Mostra tutto
Gilead Sciences Inc Borsa (GILD) Ultime notizie
Gilead Sciences director Jeffrey Bluestone sells $725,077 in stock - Investing.com
Gilead Sciences director Jeffrey Bluestone sells $725,077 in stock By Investing.com - Investing.com UK
Gilead Sciences (NASDAQ:GILD) Director Sells 5,000 Shares of Stock - MarketBeat
Gilead Sciences (GILD) director sells 5,000 shares near $146 - Stock Titan
Portfolio Design Labs LLC Takes $1.29 Million Position in Gilead Sciences, Inc. $GILD - MarketBeat
PCM Encore LLC Buys Shares of 7,399 Gilead Sciences, Inc. $GILD - MarketBeat
Vise Technologies Inc. Takes $15.17 Million Position in Gilead Sciences, Inc. $GILD - MarketBeat
14,265 Shares in Gilead Sciences, Inc. $GILD Purchased by OVERSEA CHINESE BANKING Corp Ltd - MarketBeat
Trillium Asset Management LLC Makes New Investment in Gilead Sciences, Inc. $GILD - MarketBeat
Allworth Financial LP Invests $5.96 Million in Gilead Sciences, Inc. $GILD - MarketBeat
Altman Advisors Inc. Takes Position in Gilead Sciences, Inc. $GILD - MarketBeat
B. Metzler seel. Sohn & Co. AG Purchases New Position in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead (NASDAQ: GILD) director to sell 5,000 shares in 2026 - Stock Titan
Gilead Sciences Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Gilead Sciences Stock Surges 11%, With A 7-Day Winning Spree - Trefis
Gilead Sciences Stock Climbs 11% On A 7-Day Winning Streak - Trefis
Zacks Research Expects Higher Earnings for Gilead Sciences - MarketBeat
Westport Asset Management Inc. Acquires Shares of 10,000 Gilead Sciences, Inc. $GILD - MarketBeat
Johnson Financial Group Inc. Invests $2.12 Million in Gilead Sciences, Inc. $GILD - MarketBeat
Tocqueville Asset Management L.P. Purchases Shares of 59,933 Gilead Sciences, Inc. $GILD - MarketBeat
NewEdge Wealth LLC Takes $95.26 Million Position in Gilead Sciences, Inc. $GILD - MarketBeat
Knuff & Co LLC Buys Shares of 17,641 Gilead Sciences, Inc. $GILD - MarketBeat
E Fund Management Co. Ltd. Acquires Shares of 53,836 Gilead Sciences, Inc. $GILD - MarketBeat
Edmond DE Rothschild Holding S.A. Purchases New Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Great Lakes Advisors LLC Buys Shares of 62,450 Gilead Sciences, Inc. $GILD - MarketBeat
59,974 Shares in Gilead Sciences, Inc. $GILD Purchased by Abacus FCF Advisors LLC - MarketBeat
Foster & Motley Inc. Takes Position in Gilead Sciences, Inc. $GILD - MarketBeat
Diversify Advisory Services LLC Invests $1.82 Million in Gilead Sciences, Inc. $GILD - MarketBeat
Does Gilead (GILD) Pairing With Nucleai Reveal a Deeper Shift in Its Oncology Strategy? - Yahoo Finance
Gilead SciencesGISStock Price & News - The Motley Fool
Publicis wins Gilead Sciences' US media account - Ad Age
Gilead Sciences Inc Stock (GILD) Moved Up by 3.66% on Aug 19: A Full Analysis - TradingKey
Gilead Sciences (GILD) CFO Andrew Dickinson Sells 3,000 Shares - GuruFocus
Zacks Research Forecasts Higher Earnings for Gilead Sciences - MarketBeat
Invesco Nasdaq Biotech vs. Invesco Pharma: How Do These ETFs Stack Up? - The Motley Fool
Meeder Advisory Services Inc. Invests $4.42 Million in Gilead Sciences, Inc. $GILD - MarketBeat
M. Kulyk & Associates LLC Buys New Position in Gilead Sciences, Inc. $GILD - MarketBeat
Pallas Capital Advisors LLC Invests $940,000 in Gilead Sciences, Inc. $GILD - MarketBeat
Great Lakes Advisors LLC Makes New $127.25 Million Investment in Gilead Sciences, Inc. $GILD - MarketBeat
13,735 Shares in Gilead Sciences, Inc. $GILD Purchased by Empirical Asset Management LLC - MarketBeat
840,400 Shares in Gilead Sciences, Inc. $GILD Purchased by Danske Bank A S - MarketBeat
Gilead Sciences Insider Sold Shares Worth $3,853,908, According to a Recent SEC Filing - marketscreener.com
Gilead Sciences CFO Andrew Dickinson sells $415k in shares - Investing.com
Andrew Dickinson Sells 3,000 Shares of Gilead Sciences (NASDAQ:GILD) Stock - MarketBeat
Gilead Sciences chief comm & corp aff officer sells $3.85m stock - Investing.com
Gilead Sciences (NASDAQ:GILD) Insider Johanna Mercier Sells 28,000 Shares of Stock - MarketBeat
Gilead (NASDAQ: GILD) CFO sells shares under 10b5-1 plan - Stock Titan
Gilead (NASDAQ: GILD) CCO sells 28,000 shares under 10b5-1 plan - Stock Titan
Gilead Sciences Inc (GILD) Stock Up 3.2% but GF Value Says Overv - GuruFocus
Gilead Sciences Inc. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
Is Gilead's Expanding HIV Portfolio a Growth Catalyst? - TradingView
Gilead Sciences Inc Azioni (GILD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Gilead Sciences Inc Azioni (GILD) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| WELTERS ANTHONY | Director |
Aug 26 '26 |
Sale |
148.62 |
18,000 |
2,675,220 |
12,894 |
1.65%
0.52%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):